Dupilumab reduces the number of lesions in adult patients with prurigo nodularis presenting with multiple lesion morphologies: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

被引：0
|
作者：
Stander, Sonja [1 ]
Yosipovitch, Gil [2 ]
Kim, Brian S. [3 ]
Hong, H. Chih-ho [4 ,5 ]
Metz, Martin [6 ,7 ]
Murota, Hiroyuki [8 ]
Gao, Xing-Hua [9 ]
de Bruin-Weller, Marjolein [10 ]
Praestgaard, Amy [11 ]
Zahn, Joseph [12 ]
Wiggins, Simmi [13 ]
机构：
[1] Univ Hosp Munster, Munster, Germany
[2] Univ Miami, Miami, FL USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Univ British Columbia, Surrey, BC, Canada
[5] Prob Med Res, Waterloo, ON, Canada
[6] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[7] Fraunhofer Inst Translat Med & Pharmacol ITMP, Allergol & Immunol, Berlin, Germany
[8] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki, Japan
[9] China Med Univ, Hosp 1, Shenyang, Peoples R China
[10] Univ Med Ctr Utrecht, Utrecht, Netherlands
[11] Sanofi, Cambridge, MA USA
[12] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[13] Sanofi, Reading, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
dupilumab; prurigo nodularis; lesions; burden;
D O I：
10.1093/bjd/ljae266.091
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
718
引用
收藏
页码：93 / 94
页数：2
相关论文
共 20 条
  • [1] Dupilumab is efficacious in patients with prurigo nodularis regardless of baseline lesion severity: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
    Staender, Sonja
    Misery, Laurent
    Yosipovitch, Gil
    Park, Chang Ook
    Li, Lin-Feng
    Praestgaard, Amy
    Zahn, Joseph
    Wiggins, Simmi
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 18 - 19
  • [2] Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
    Yosipovitch, Gil
    Kim, Brian S.
    Kwatra, Shawn G.
    Mollanazar, Nicholas K.
    Stander, Sonja
    Satoh, Takahiro
    Mendes-Bastos, Pedro
    Tsai, Tsen-Fang
    Laws, Elizabeth
    Nivens, Michael C.
    Maloney, Jennifer
    Shi, Genming
    Bansal, Ashish
    Dubost-Brama, Ariane
    JAAD INTERNATIONAL, 2024, 16 : 163 - 174
  • [3] Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
    Yosipovitch, Gil
    Kwatra, Shawn G.
    Mollanazar, Nicholas
    Staender, Sonja
    Satoh, Takahiro
    Laws, Elizabeth
    Mannent, Leda P.
    Mortensen, Eric
    Maloney, Jennifer
    Shi, Genming
    Bansal, Ashish
    Martincova, Renata
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [4] Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (liberty-pn prime and prime2)
    Yosipovitch, G.
    Kwatra, S. G.
    Mollanazar, N.
    Staender, S.
    Satoh, T.
    Laws, E.
    Mannent, L. P.
    Mortensen, E.
    Maloney, J.
    Shi, G.
    Bansal, A.
    Martincova, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S111 - S111
  • [5] Dupilumab is efficacious in patients with prurigo nodularis regardless of history of atopic comorbidities: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
    Kim, Brian S.
    Goncalo, Margarida
    Ugajin, Tsukasa
    Praestgaard, Amy
    Makhija, Melanie
    Zahn, Joseph
    Bansal, Ashish
    Wiggins, Simmi
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II11 - II12
  • [6] Dupilumab improves itch and skin lesions in North American patients with prurigo nodularis: a subset analysis of the pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
    Elmariah, Sarina B.
    Mollanazar, Nicholas
    Hong, H. Chi-ho
    Walker, Kirsten
    Butler, Daniel C.
    Praestgaard, Amy
    Zahn, Joseph
    Wiggins, Simmi
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [7] Dupilumab is efficacious in patients above and below 60 years old with prurigo nodularis: pooled results from two phase III trials (LIBERTY-PN PRIME and PRIME2)
    Kwatra, Shawn G.
    Staender, Sonja
    Bewley, Anthony
    Tsai, Tsen-Fang
    Fujita, Hideki
    Praestgaard, Amy
    Zahn, Joseph
    Wiggins, Simmi
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I54 - I54
  • [8] Dupilumab is efficacious in patients with prurigo nodularis regardless of stable use of topical corticosteroids and topical calcineurin inhibitors: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
    Kim, Brian S.
    Yosipovitch, Gil
    Kwatra, Shawn G.
    Staender, Sonja
    Mollanazar, Nicholas
    Shi, Genming
    Bansal, Ashish
    Makhija, Melanie
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II14 - II15
  • [9] Dupilumab Improves Multiple Factors Impacting Quality of Life in Adults With Prurigo Nodularis (LIBERTY-PN PRIME and PRIME2)
    Kwatra, Shawn G.
    Yosipovitch, Gil
    Mollanazar, Nicholas
    Staender, Sonja
    Kim, Brian S.
    Msihid, Jerome
    Bansal, Ashish
    O'Malley, John T.
    Bahloul, Donia
    Thomas, Ryan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB150 - AB150
  • [10] Dupilumab Improves Disease-Specific Quality of Life in Patients With Prurigo Nodularis (LIBERTY-PN PRIME and PRIME2)
    Kwatra, Shawn
    Yosipovitch, Gil
    Mollanazar, Nicolas
    Stander, Sonja
    Kim, Brian S.
    Msihid, Jerome
    Bansal, Ashish
    O'Malley, John T.
    Bahloul, Donia
    Thomas, Ryan B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB39 - AB39
12